Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real‐world cohort analysis

In a European cohort of people diagnosed late with HIV who started first-line ART either with 2DR DTG/3TC or 3DR BIC/TAF/FTC, there were no significant differences in virological response and discontinuation rates after 48 weeks of treatment. With respect to the relatively small sample size and the inherent constraints of the study design, the possibility of establishing causal inference remains limited, and prospective studies are needed to further investigate on this topic.

Authors

Institutions

Publication Details

Journal
HIV Medicine
Published
2025-10-07
DOI
https://doi.org/10.1111/hiv.70119
Primary Topic
HIV/AIDS drug development and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real‐world cohort analysis

Federico Pulido, Eugènia Negredo, Roser Navarro‐Soler, Alfonso Cabello et al.
HIV Medicine
HIV/AIDS drug development and treatment
article

Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real‐world cohort analysis

Federico Pulido, Eugènia Negredo, Roser Navarro‐Soler, Alfonso Cabello, Gundolf Schuettfort, Rafael Micán, Christoph Stephan, Jörg Janne Vehreschild, Sebastian Noé, Rosário Serrão, Jordi Puig, Jürgen Kurt Rockstroh, Carmen Hidalgo‐Tenorio, Eva Herrmann, Sergio Rodrı́guez, María José Crusells, Miguel Torralba, Annette E. Haberl, Juan Carlos López, Miguel Górgolas, Diva Trigo, Jan Borch
article en

Abstract

In a European cohort of people diagnosed late with HIV who started first-line ART either with 2DR DTG/3TC or 3DR BIC/TAF/FTC, there were no significant differences in virological response and discontinuation rates after 48 weeks of treatment. With respect to the relatively small sample size and the inherent constraints of the study design, the possibility of establishing causal inference remains limited, and prospective studies are needed to further investigate on this topic.

HIV MedicineVol. 27(1)
Goethe University Frankfurt (DE), Universitat de Vic - Universitat Central de Catalunya (ES), University Hospital Bonn (DE), Hospital Universitario La Paz (ES), Hospital General Universitario Gregorio Marañón (ES), Hospital de São João (PT), Hospital Universitario de Guadalajara (ES), Hospital Prof. Dr. Fernando Fonseca (PT), Hospital Universitario 12 De Octubre (ES), Hospital Universitario de Getafe (ES), Goethe Institut (DE), Hospital Universitario Virgen de las Nieves (ES), Hospital Universitario Fundación Jiménez Díaz (ES), University Hospital Frankfurt (DE), Hospital Clínico Universitario Lozano Blesa (ES), Universidad Autónoma de Madrid (ES), Praxis (EE)
Openalex Percentile: Top 67%
HIV/AIDS drug development and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.